Gelesis Holdings, Inc.

OTCPK:GLSH Stock Report

Market Cap: US$850.7k

Gelesis Holdings Valuation

Is GLSH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GLSH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GLSH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GLSH's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLSH?

Key metric: As GLSH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GLSH. This is calculated by dividing GLSH's market cap by their current revenue.
What is GLSH's PS Ratio?
PS Ratio0.07x
SalesUS$12.14m
Market CapUS$850.69k

Price to Sales Ratio vs Peers

How does GLSH's PS Ratio compare to its peers?

The above table shows the PS ratio for GLSH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.1x
RGBP Regen BioPharma
3.8xn/aUS$893.9k
BLCM Bellicum Pharmaceuticals
0.6xn/aUS$879.5k
AXIM AXIM Biotechnologies
7.8xn/aUS$725.9k
SQZB SQZ Biotechnologies
0.07xn/aUS$825.8k
GLSH Gelesis Holdings
0.07xn/aUS$850.7k

Price-To-Sales vs Peers: GLSH is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.8x).


Price to Sales Ratio vs Industry

How does GLSH's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.6x21.4%
GLSH Gelesis Holdings
0.07xn/aUS$850.69k
GILD Gilead Sciences
4x2.4%US$112.40b
BIIB Biogen
2.4x1.3%US$23.01b
GLSH 0.1xIndustry Avg. 9.6xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.6x28.3%
GLSH Gelesis Holdings
0.07xn/aUS$850.69k
No more companies

Price-To-Sales vs Industry: GLSH is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Biotechs industry average (10.9x).


Price to Sales Ratio vs Fair Ratio

What is GLSH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLSH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.07x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GLSH's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies